Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 21, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the submission of the "Results of Meeting" as Exhibit 99.1. No financial performance changes versus prior periods are detailed in this specific filing text.
Guidance, Outlook, and Risks
The filing incorporates this report by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076). No specific management commentary, guidance, or risk factors are explicitly stated within the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 ("Results of Meeting") for specific details on the corporate action or meeting outcomes.
- Verify the impact of the meeting results on the referenced Form S-8 and Form F-3 registration statements.
- Confirm the company's status as a development stage enterprise and its current cash runway, as no financial data is present in this summary.